GEN-XENE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GEN-XENE (GEN-XENE).

How it works

Benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.

What the body does with it

Metabolism	Hepatic via CYP3A4; active metabolite N-desmethyldiazepam; also undergoes glucuronidation.
Excretion	Renal: ~80% as glucuronide and oxidized metabolites; fecal: ~20% via biliary excretion.
Half-life	30–100 hours (mean ~50 h); prolonged in elderly and hepatic impairment; steady-state achieved in 7–10 days.
Protein binding	95–99% bound, primarily to albumin.
Volume of Distribution	0.5–2.0 L/kg; indicates extensive tissue distribution.
Bioavailability	Oral: 85–100%; rectal: 90%.
Onset of Action	Oral: 30–60 minutes; rectal: 15–30 minutes; IV: 2–5 minutes.
Duration of Action	6–12 hours (single dose), up to 24 hours with accumulation; prolonged with high doses or chronic use.

Classification & Brands

Dosing & administration

Initial: 10 mg PO TID; maintenance: 20-40 mg/day PO in divided doses; max: 120 mg/day.

Dosage form	TABLET
Renal impairment	CrCl 30-60 mL/min: reduce dose by 50%; CrCl <30 mL/min: use not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Pediatric use	Not recommended for use in children under 6 years; for children ≥6 years: initial 5 mg PO BID, titrate as needed up to 60 mg/day.
Geriatric use	Initial: 5 mg PO BID; increase slowly; max: 60 mg/day; increased sensitivity to CNS effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GEN-XENE (GEN-XENE).

Breastfeeding	Excreted into breast milk; M/P ratio approximately 0.1-0.5. Avoid breastfeeding due to risk of infant sedation, poor feeding, and potential accumulation. Consider alternative agents.
Teratogenic Risk	First trimester: Increased risk of congenital malformations (e.g., oral clefts) with exposure. Second and third trimesters: Risk of CNS depression, hypotonia, respiratory depression (floppy infant syndrome), and withdrawal symptoms in neonates. Late third trimester or delivery: Potential for neonatal withdrawal syndrome.

Warnings & precautions

■ FDA Black Box Warning

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to clorazepate or other benzodiazepines","Acute narrow-angle glaucoma","Pre-existing CNS depression","Severe hepatic impairment","Pregnancy (especially first trimester)"]

Clinical Precautions

Precautions

["Risk of dependence and withdrawal reactions after prolonged use","CNS depressant effects may impair mental alertness","Use with caution in elderly and debilitated patients due to increased sensitivity and fall risk","May cause anterograde amnesia","Should not be abruptly discontinued after long-term use"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

GEN-XENE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for GEN-XENE (GEN-XENE).

How it works

Benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and neuronal inhibition.

What the body does with it

Metabolism	Hepatic via CYP3A4; active metabolite N-desmethyldiazepam; also undergoes glucuronidation.
Excretion	Renal: ~80% as glucuronide and oxidized metabolites; fecal: ~20% via biliary excretion.
Half-life	30–100 hours (mean ~50 h); prolonged in elderly and hepatic impairment; steady-state achieved in 7–10 days.
Protein binding	95–99% bound, primarily to albumin.
Volume of Distribution	0.5–2.0 L/kg; indicates extensive tissue distribution.
Bioavailability	Oral: 85–100%; rectal: 90%.
Onset of Action	Oral: 30–60 minutes; rectal: 15–30 minutes; IV: 2–5 minutes.
Duration of Action	6–12 hours (single dose), up to 24 hours with accumulation; prolonged with high doses or chronic use.

Classification & Brands

Dosing & administration

Initial: 10 mg PO TID; maintenance: 20-40 mg/day PO in divided doses; max: 120 mg/day.

Dosage form	TABLET
Renal impairment	CrCl 30-60 mL/min: reduce dose by 50%; CrCl <30 mL/min: use not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Pediatric use	Not recommended for use in children under 6 years; for children ≥6 years: initial 5 mg PO BID, titrate as needed up to 60 mg/day.
Geriatric use	Initial: 5 mg PO BID; increase slowly; max: 60 mg/day; increased sensitivity to CNS effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for GEN-XENE (GEN-XENE).

Breastfeeding	Excreted into breast milk; M/P ratio approximately 0.1-0.5. Avoid breastfeeding due to risk of infant sedation, poor feeding, and potential accumulation. Consider alternative agents.
Teratogenic Risk	First trimester: Increased risk of congenital malformations (e.g., oral clefts) with exposure. Second and third trimesters: Risk of CNS depression, hypotonia, respiratory depression (floppy infant syndrome), and withdrawal symptoms in neonates. Late third trimester or delivery: Potential for neonatal withdrawal syndrome.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to clorazepate or other benzodiazepines","Acute narrow-angle glaucoma","Pre-existing CNS depression","Severe hepatic impairment","Pregnancy (especially first trimester)"]